A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
about
Marine Invertebrate Metabolites with Anticancer Activities: Solutions to the "Supply Problem"Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics.Cyanobacteria: an emerging source for drug discovery.ET743: Chemical analysis of the sea squirt Ecteinascidia turbinata ecosystem.A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancieMarine compounds selectively induce apoptosis in female reproductive cancer cells but not in primary-derived human reproductive granulosa cellsPhase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.Sepia ink oligopeptide induces apoptosis in prostate cancer cell lines via caspase-3 activation and elevation of Bax/Bcl-2 ratioPhase II Trial of Dolastatin-10, a Novel Anti-Tubulin Agent, in Metastatic Soft Tissue SarcomasMicrotubule dynamics as a target in oncology.Marine natural product drug discovery: Leads for treatment of inflammation, cancer, infections, and neurological disorders.The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics.Antitumor bioactive peptides isolated from marine organisms.Sepia ink oligopeptide induces apoptosis and growth inhibition in human lung cancer cells.Determination and stress studies on YK-1101, a potential histone deacetylase, by HPLC-UV and HPLC-TOF/MS methods.Epothilones and new analogues of the microtubule modulators in taxane-resistant disease
P2860
Q26746924-BA4A655A-3160-4805-AD80-DA6EC345834CQ26781365-8E950B0E-BDE4-455A-8A8A-52BFCC5671F0Q30444706-10E44342-DAA1-4791-BB9F-79351B2AE38CQ33863512-722AF53E-CF6F-471F-8985-589AB62FD08DQ34566870-91C3553E-BA99-48F3-9794-F3EF7FA7BE08Q35000494-8B84496D-F394-40CC-BB0F-A4A78D0BE8F8Q35759919-1C506FF0-DF03-4B81-A4BA-AF99BA5D2AA7Q35913613-3C15C9CD-C71B-4FAF-8820-F1561C2BE1FFQ36395784-DEE7C088-7186-4A95-A8FB-C6A8A50FF479Q36674450-361F4E1E-AE4A-45D2-9674-AFAA364931DBQ37360708-78525D0B-A3CE-4B5E-9D83-8D4926276901Q37742166-304814F8-FB69-49EB-9653-004A4B268884Q38092648-2CBD1759-1DAF-40A5-B913-63FE8CCDB57DQ38663010-0E3B1BA8-1443-4454-9396-4F90D671B492Q41766104-F60CD6C8-379D-43FE-B7A7-622F86DC9B9FQ49769675-9C014517-D5C9-4254-8602-2D3BAF434479Q57244875-7BC58C7F-C0FF-4919-B6AC-3C43D6F64114
P2860
A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
A phase II trial of dolastatin ...... ecologic Oncology Group study.
@en
A phase II trial of dolastatin ...... ecologic Oncology Group study.
@nl
type
label
A phase II trial of dolastatin ...... ecologic Oncology Group study.
@en
A phase II trial of dolastatin ...... ecologic Oncology Group study.
@nl
prefLabel
A phase II trial of dolastatin ...... ecologic Oncology Group study.
@en
A phase II trial of dolastatin ...... ecologic Oncology Group study.
@nl
P2093
P1433
P1476
A phase II trial of dolastatin ...... ecologic Oncology Group study.
@en
P2093
Gynecologic Oncology Group Study
John A Blessing
Mark A Hoffman
Samuel S Lentz
P356
10.1016/S0090-8258(03)00007-6
P407
P577
2003-04-01T00:00:00Z